1.
					
							The Influence of Different Thromboplastins Upon the International Normalised ratio (INR) and the Prothrombin Time Ratio (PTR)
						
						
						组织凝血活酶对凝血酶原时间比率与国际正常化比率的影响
					2.
					
							Comparison of activated partial thromboplastion time reagent between made by oneself and imported reagent
						
						
						自制与进口活化部分凝血活酶试剂的比较
					3.
					
							Determination standard of abnormal result for activated partial thromboplastin time
						
					
					
						
						
					
					
						活化的部分凝血活酶时间异常结果的判定标准
					4.
					
							Calibration of Human Placenta Thromboplastin and it′s Clinical Uses
						
					
					
						
						
					
					
						人胎盘凝血活酶试剂的标定及其临床应用
					5.
					
							Change and Clinical Significance of Serum AT-Ⅲ in Patients with Ischemic Stroke Disease
						
					
					
						
						
					
					
						血浆抗凝血活酶Ⅲ活性在急性脑梗死中的变化及其临床意义
					6.
					
							Study on the Relationship of Mutation of Prothrombin G20210A,Activated Protein C Resistance and Antithrombin in Patients with Coronary Heart Disease;
						
						
						凝血酶原G20210A突变、抗活化蛋白C和抗凝血酶与冠心病关系的研究
					7.
					
							Prokaryotic Expression,Purification and Procoagulant Activity Analysis of Recombinant Fibrinogen-related Domain Protein of Human fgl2 Prothrombinase
						
						
						人fgl2凝血酶原酶FRED结构域的原核表达、纯化及其凝血活性的鉴定
					8.
					
							Coagulation Activity of Gln49-PLA_2 from Gloydius Ussuriensis Snake Venom in Vitro;
						
					
					
						
						
					
					
						白眉蝮蛇毒Gln49磷脂酶A_2体外凝血活性
					9.
					
							Determination of Thrombin Inhibitor Activity by Absorbance rate of Change;
						
					
					
						
						
					
					
						一种测定凝血酶抑制剂活性的新方法
					10.
					
							The Diagnostic Significance of Antithrombin in Disseminated Intravascular Coagulation (DIC)
						
						
						抗凝血酶活性检测在诊断弥散性血管内凝血中的意义
					11.
					
							Mechanisms of Actions of Protease-activated Receptors 1 and 4 in Platelet Activation;
						
					
					
						
						
					
					
						凝血酶受体PAR1与PAR4在血小板活化中的作用机制
					12.
					
							Studies on the Thrombin Activatable Fibrinolysis Inhibitor of Coronary Atherosclerotic Heart Disease;
						
						
						冠心病患者凝血酶激活的纤溶抑制物研究
					13.
					
							Influence of Aprotinin to Activated Clotting Time and Whole Blood Prothrombin Time during Cardiopulmonary Bypass;
						
						
						体外循环下抑肽酶对激活的全血凝固时间和全血凝血酶原时间的影响
					14.
					
							Clinical Research on Activation of Platelet and Prothrombin after Transcatheter Closure of Atrial Septal Defects;
						
						
						房间隔缺损封堵术后血小板活化和凝血酶原激活临床研究
					15.
					
							tissue thromboplasti
						
					
					
						
						
					
					
						组织促凝血酶原激酶
					16.
					
							thromboplastin antecedent
						
					
					
						
						
					
					
						促凝血酶原激酶先质
					17.
					
							Relationship between Thrombin Activated Fibrinolysis Inhibitor in Plasma and Vascular Complication in Type 2 Diabetes;
						
						
						血浆凝血酶激活的纤溶抑制物与2型糖尿病血管并发症的关系
					18.
					
							Nucleocapsid Protein of SARS-associated Coronavirus Upregulates the Transcription of hfgl2 Prothrombinase/ Fibroleukin Gene;
						
						
						SARS冠状病毒N蛋白激活hfgl2凝血酶原酶基因的研究